Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hospira has launched irinotecan hydrochloride injection in the US for patients with colon or rectal cancer whose disease has recurred or progressed following therapy with other treatments.
Subscribe to our email newsletter
The medication is a generic version of Pfizer’s Camptosar. Hospira’s irinotecan product portfolio extends beyond the formulations available from the innovator. In addition to offering the medication in 40mg and 100mg single-dose vials, Hospira is also marketing a 500mg single-dose vial, for additional convenience when preparing and delivering larger doses. The company packages irinotecan in its proprietary Onco-Tain vials for safe handling.
Robert Felicelli, vice president and general manager of Hospira, said: “We are continuing to grow our leading portfolio of generic medications used to treat patients with cancer. By providing irinotecan and other high-quality, lower-cost alternatives to proprietary medications, Hospira is meeting patient needs in this fast-growing therapeutic area.”